Nirmatrelvir/ritonavir + Placebo/ritonavir
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Post-COVID-19 Syndrome
Conditions
Post-COVID-19 Syndrome, Long COVID, Long Covid19, COVID-19, POTS - Postural Orthostatic Tachycardia Syndrome, Post COVID-19 Condition, Post-COVID Syndrome, Post COVID-19 Condition, Unspecified, Postinfectious Inflammation, Postinfectious Disorder
Trial Timeline
May 1, 2023 → Nov 28, 2024
NCT ID
NCT05823896About Nirmatrelvir/ritonavir + Placebo/ritonavir
Nirmatrelvir/ritonavir + Placebo/ritonavir is a phase 2 stage product being developed by Pfizer for Post-COVID-19 Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT05823896. Target conditions include Post-COVID-19 Syndrome, Long COVID, Long Covid19.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05823896 | Phase 2 | Completed |
Competing Products
2 competing products in Post-COVID-19 Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Meplazumab for injection | Pacific Biosciences | Phase 3 | 69 |
| Vortioxetine + Placebo | Brain Biotech | Phase 2 | 44 |